Profile data is unavailable for this security.
About the company
Khiron Life Sciences Corp. is a Canada-based medical cannabis company with core operations in Latin America. The Company has its wholly owned medical health clinics and telemedicine platforms. The Company has two product lines: Medical Cannabis Products and Health Services. It sells branded medical cannabis products to patients with medical conditions. Under the Medical Cannabis Products line, the Company is focused on product sales in Latin America. The Company operates its own network of health centers (operating under the Zerenia brand) and Zerenia satellite clinics offering a suite of health, medical and surgical services, in alignment with both insurance company partners and private practice. Its subsidiaries include Khiron Life Sciences Corp. (Canada), Khiron Colombia S.A.S., Zerenia S.A.S., NettaGrowth International Inc., and others.
- Revenue in CAD (TTM)16.14m
- Net income in CAD-30.66m
- Incorporated2012
- Employees310.00
- LocationKhiron Life Sciences Corp100 King Street West, Suite 1600TORONTO M5X 1G5CanadaCAN
- Phone+1 (647) 556-5750
- Fax+1 (705) 527-3564
- Websitehttps://khiron.ca/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
XORTX Therapeutics Inc | 0.00 | -4.59m | 7.84m | 3.00 | -- | 2.29 | -- | -- | -1.93 | -1.93 | 0.00 | 1.18 | 0.00 | -- | -- | -- | -42.59 | -35.42 | -45.30 | -40.37 | -- | -- | -- | -- | -- | -- | 0.0056 | -- | -- | -- | 72.04 | -- | 7.91 | -- |
Therma Bright Inc | 25.80k | -2.88m | 7.90m | -- | -- | 4.31 | -- | 306.12 | -0.0115 | -0.0115 | 0.0001 | 0.0058 | 0.0076 | 0.0023 | 0.115 | -- | -84.40 | -220.66 | -165.23 | -444.57 | 98.45 | -- | -11,152.48 | -10,853.16 | 0.0447 | -184.52 | 0.0411 | -- | -82.86 | 11.13 | 35.93 | -- | 40.15 | -- |
Crescita Therapeutics Inc | 17.92m | -2.34m | 8.38m | 78.00 | -- | 0.4631 | -- | 0.4676 | -0.1162 | -0.1162 | 0.8927 | 0.9285 | 0.6903 | 1.50 | 4.62 | -- | -9.01 | -0.2457 | -11.40 | -0.3059 | 56.03 | 63.41 | -13.06 | -0.3518 | 2.60 | -- | 0.0594 | -- | -25.52 | 1.05 | -330.39 | -- | -1.58 | -- |
Khiron Life Sciences Corp | 16.14m | -30.66m | 9.30m | 310.00 | -- | -- | -- | 0.5761 | -0.1674 | -0.1674 | 0.085 | 0.1248 | 0.3078 | 1.33 | 3.90 | 52,055.68 | -58.47 | -- | -69.10 | -- | 19.51 | -- | -190.00 | -- | 0.9133 | -- | 0.0864 | -- | 59.60 | -- | -37.81 | -- | -- | -- |
Valeo Pharma Inc | 54.86m | -29.77m | 10.85m | 80.00 | -- | -- | -- | 0.1979 | -0.3273 | -0.3273 | 0.6054 | -0.5561 | 1.32 | 4.45 | 9.31 | 438,864.00 | -71.78 | -64.35 | -330.86 | -113.22 | 18.32 | 23.88 | -54.26 | -69.71 | 0.2738 | -1.31 | 5.32 | -- | 94.31 | 65.20 | -8.01 | -- | 76.61 | -- |
Holder | Shares | % Held |
---|---|---|
Purpose Investments, Inc.as of 31 May 2024 | 500.00k | 0.00% |
FNY Capital Management LPas of 31 Mar 2024 | 1.00k | 0.00% |